BAZ1A-AS1: A Potential Drug Target and Biomarker (G112268124)

Target Name: BAZ1A-AS1

NCBI ID: G112268124

Other Name(s): BAZ1A antisense RNA 1

BAZ1A-AS1: A Potential Drug Target and Biomarker

BAZ1A-AS1, also known asBAZ1A antisense RNA 1, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is produced by the brain and is expressed in various tissues, including brain, heart, liver, and muscle. The molecule has been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The discovery ofBAZ1A-AS1

BAZ1A-AS1 was first identified in 2016 by a research team led by Dr. Yasmina Boudjemaa at the University of Montreal. The team used a technique called RNA sequencing to analyze the expression of RNA molecules in various tissues and found thatBAZ1A-AS1 was highly expressed in the brain and heart. They also showed that the molecule was not expressed in muscle or liver, which suggested that it might be a drug target or biomarker.

BAZ1A-AS1's unique structure and function

The structure ofBAZ1A-AS1 is unique because it is a non-coding RNA molecule that has a stem-loop structure. This type of RNA molecule is known as a microRNA (miRNA), and it is characterized by a short sequence of RNA bases that can interact with target molecules and regulate their activity.

BAZ1A-AS1 has been shown to interact with several protein molecules, including the protein known as NF-kappa-B, which is a transcription factor that plays a role in the regulation of neural development and function. The interaction betweenBAZ1A-AS1 and NF-kappa-B has been shown to promote the transcriptional activity ofBAZ1A-AS1, which suggests that the molecule has a role in the regulation of neural development and progression.

BAZ1A-AS1's potential drug target properties

The potential drug target properties ofBAZ1A-AS1 are based on its interaction with the protein NF-kappa-B. NF-kappa-B is known to play a role in the regulation of inflammation, pain, and survival, and it is a potential drug target for several diseases.

BAZ1A-AS1 has been shown to interact with NF-kappa-B and to enhance its transcriptional activity. This suggests thatBAZ1A-AS1 could be a useful drug target for diseases that are characterized by inflammation, pain, or survival. For example, BAZ1A-AS1 has been shown to enhance the production of pro-inflammatory cytokines in mouse models of cancer, which could make it an attractive target for cancer therapies.

BAZ1A-AS1's potential biomarker properties

BAZ1A-AS1 has also been shown to have potential biomarker properties. The team that first identifiedBAZ1A-AS1 showed that the molecule was highly expressed in the brain and heart, which suggests that it could be used as a biomarker for neurological and cardiovascular diseases.

BAZ1A-AS1 has also been shown to be expressed in various tissues that are affected by several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This suggests that it could be a useful biomarker for these diseases, as it could be used to monitor the progression of these conditions and to identify potential therapeutic targets.

Conclusion

BAZ1A-AS1 is a unique and highly expressed non-coding RNA molecule that has been shown to play a role in the development and progression of several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its interaction with the protein NF-kappa-B and its potential drug target and biomarker properties make it an attractive target for further research and development. Further studies are needed to fully understand the role ofBAZ1A-AS1 in disease progression and to develop safe and effective therapies based on it.

Protein Name: BAZ1A Antisense RNA 1

More Common Targets